Medfinder
Chemon 91
Hydroxychloroquine' being administered to 1,100 COVID19 patients in New York: US President Donald Trump
An inexpensive drug widely used since 1955 to treat malaria, Hydroxychloroquine is considered to have relatively harmless side effects. It is being tested out on the COVID-19 patients in New York on an experimental basis,
"The FDA is also allowing the emergency use of a blood-related therapy called convalescent plasma as an experimental treatment for seriously ill patients," said the president.
Given the drug's relatively harmless side effects, doctors are already beginning to incorporate the drug in their treatment of the coronavirus cases. President Trump and New York Governor Andrew Cuomo have both expressed optimism over the drug's efficacy.
In a statement, Health and Human Services said that FDA has allowed the drugs to be "donated to the Strategic National Stockpile to be distributed and prescribed by doctors to hospitalised teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
Novartis's Sandoz has donated 30 million doses of Hydroxychloroquine to the stockpile and Bayer donated 1 million doses of chloroquine, the media statement said. Both the drugs have been evaluated for the use against COVID-19 in clinical trials around the world.
An inexpensive drug widely used since 1955 to treat malaria, Hydroxychloroquine is considered to have relatively harmless side effects. It is being tested out on the COVID-19 patients in New York on an experimental basis,
"The FDA is also allowing the emergency use of a blood-related therapy called convalescent plasma as an experimental treatment for seriously ill patients," said the president.
Given the drug's relatively harmless side effects, doctors are already beginning to incorporate the drug in their treatment of the coronavirus cases. President Trump and New York Governor Andrew Cuomo have both expressed optimism over the drug's efficacy.
In a statement, Health and Human Services said that FDA has allowed the drugs to be "donated to the Strategic National Stockpile to be distributed and prescribed by doctors to hospitalised teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible."
Novartis's Sandoz has donated 30 million doses of Hydroxychloroquine to the stockpile and Bayer donated 1 million doses of chloroquine, the media statement said. Both the drugs have been evaluated for the use against COVID-19 in clinical trials around the world.